Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status

Table 3 Summary of cytapheresis

Treatment	Adsorbent	Blood volume	Common mechanism	Advantages/ features	Diseases	Contrain-dications	Major adverse events reported
GCAP/GMA	Cellulose acetate	1.5-2.0 L	Mobilization of naive leukocytes by activated leukocyte removal; Inhibition of Cellular Invasion of Activated Leukocytes; Suppression of inflammatory cytokines, increase of anti-inflammatory cytokines	High specificity for removing WBCs. 30%-50% removal of granulocytes and monocytes, and approximately 6% removal of lymphocytes	Ulcerative colitis; Crohn's disease; Pustular psoriasis; Pyoderma Gangrenosum	Granulocyte < 2000/mm3 associated with infection	Allergic symptoms; Nausea; Fever; Aabdominal oppression; Headache
LCAP	Polyethylene-telephthalate	2.0-4.0 L		High efficiency for removing WBCs Almost all granulocytes and monocytes, and 40%-60% of lymphocytes and platelets can be removedIncrease of naive T cells can be seen and its therapeutic effect can be expected by suppressing antibody production and immune reaction	Ulcerative colitis; Rheumatoid arthritis	Treatment with angiotensin-converting enzyme inhibitors

GCAP: Granulocytapheresis; LCAP: Leukocytapheresis; WBC: White blood cell.